Sun Pharma Reportedly Near $12 Billion Deal for Organon, Stock Jumps 25%
NEW YORK, April 11 —
Organon shares surged 25% to $8.83 on reports that Sun Pharmaceutical is nearing a $12 billion all-cash acquisition.
- OGN up 25% on the session, trading at $8.83 after the takeover report
- Reported deal value of ~$12bn against $6.2bn TTM revenue, roughly 1.9x sales
- Forward P/E sat at just 2.4x before the news, one of the cheapest multiples in large-cap pharma
What Actually Happened
Multiple sources report Sun Pharma is close to finalizing a cash deal for Organon, the women's health and biosimilars company Merck spun off in 2021. The reported $12bn price tag would make this one of the largest pharma acquisitions of the year. At 1.9x trailing revenue, it is not a generous offer by pharma M&A standards, where deals routinely close north of 3x. But Organon is not a typical pharma target. The company carried heavy debt from the Merck spinoff, and a significant chunk of that $12bn figure likely covers debt assumption rather than equity premium. That distinction matters enormously for what shareholders actually receive per share.
The Catch
A stock trading at 2.4x forward earnings that only pops 25% on a reported buyout is telling you something. The market is pricing in real doubt that this deal closes at terms favorable to equity holders. Organon's debt load means the gap between enterprise value and equity value is wide. Shareholders need to watch the per-share offer price, not the headline $12bn number. There is also regulatory risk: Sun Pharma is India's largest pharma company by market cap, and a cross-border deal of this size will draw scrutiny from multiple antitrust authorities. Until there is an official bid with a specific per-share price, the spread between where OGN trades and what holders actually get remains a guess.
Bottom Line
This is a company the market had left for dead. A 2.4x forward P/E on $6.2bn in revenue is not a valuation. It is a dare. Sun Pharma taking that dare makes strategic sense: Organon's Nexplanon franchise and biosimilar portfolio give Sun a ready-made diversified platform outside India. For current holders, the 25% move is real money, but chasing the stock here is a bet on deal certainty with limited visibility on final terms. The number to watch is the confirmed per-share offer price and how much of the $12bn headline is equity versus debt assumption.
Organon does not yet have a Basis Report. Generate a full OGN equity report here to see the complete financial picture.
Basis Report does not hold positions in securities discussed. This is not investment advice.